Pinned Tweet
The 2021 U.S. Generic and Biosimilar Medicines Savings Report reveals that in 2020 alone, #biosimilars generated nearly $8 billion in savings, more than tripling 2019 savings. #GlobalBiosimilarsWeek
Read more in this blog post from the @BiosimsCouncil ⬇️biosimilarscouncil.org/resou…
The @BiosimsCouncil's comment to the @FTC today outlines harmful Pharmacy Benefit Manager practices: https://teapawt.net/t.co/Qf1l6daZAe
#Biosimilars are lower cost options, but too often PBMs do not encourage their use.
Today I will be joining @HCRoundtable for the webinar, "Biosimilars in the US: Benefits, Public Policies and Opportunities."
Register to hear perspectives from the @BiosimsCouncil and @Sandoz_Global on the evolving #biosimilar policy landscape: https://teapawt.net/t.co/LDlKvHjBOq
This is #MarkupMadness. Stop middlemen from adding to the cost of the generic prescription medicines millions of America’s patients rely on each day to manage their health! markupmadness.org
3
It was great to speak backstage with @LachmanConsult's Frances Zipp, @amcporg's Susan Cantrell (@amcpceo), and @Sandoz_Global's Keren Haruvi back stage at #Access2022! They shared great ideas about how to inspire the next generation of women in health care. #WiHP #Access2022
Today at #Access2022, I will be joined by Martin Ares from @Sandoz_Global, Bret Jackson from @EAMOnline, Steven Allison from @AdventHealth and Steve Miller from @Cigna for "Leveraging Biosimilar Competition for Success."
You won't want to miss it!
I said that I love you
But got back only crickets
Are you with the #biosimilars,
Stuck in the patent thickets?
#HealthPolicyValentines
4
Valentine, I love you ❤️
And you say you love me
If Medicare Plans love #generics
Why are most now on brand tiers in Part D?
Valentine, I need more of you
And I know our future is bright.
Ditto for #biosimilars 💉
So let’s get the policies right.
#HealthPolicyValentines
The @BiosimsCouncil looks forward to continuing our mission to increase patient access to #biosimilars this year.
Read our latest blog post to catch a glimpse into what's on our agenda in 2022: biosimilarscouncil.org/resou…
Next week at #Access2022 I will be joined by Steven Allison (@stevenallisonrx), Martin Arès, Bret Jackson & Dr. Steve Miller to discuss the various stakeholders leveraging #biosimilar competition today.
Don't miss out! Register here: access.accessiblemeds.org
@BiosimsCouncil
At @AccessibleMeds & @BiosimsCouncil, we're looking forward to #Access2022, our preeminent conference taking place on Feb. 14-16.
I hope to see you all there in person in Orlando, FL to discuss what the future holds for the #biosimilars industry: youtube.com/watch?v=yUNCl6SZ…
Between participating in Global Biosimilars Week and hosting the GRx+Biosims 2021 conference, November was a busy month for the @BiosimsCouncil.
Read our November #Biosimilars Bulletin to learn more ➡️ biosimilarscouncil.org/resou…
The negotiation framework in #BuildBackBetter undermines tremendous savings generated by the #biosimilars industry and constrains patient access in the process.
The evidence is clear. Read our latest blog post from the @BiosimsCouncil to learn more: https://teapawt.net/t.co/yMPPqANfr2
#GRxBiosims 2021 is next week (Nov. 8-10), and I invite you to join @AccessibleMeds & the @BiosimsCouncil for three days packed with invaluable insights and information on #biosimilars & #generics from industry experts.
Register here ➡️ grxbiosims.org/
4
We are just one week away from #GRxBiosims 2021, and I invite you to join @AccessibleMeds & the @BiosimsCouncil virtually Nov. 8-10 to meet the leaders and decision-makers who are determining the future of generics and #biosimilars.
Register here ➡️ grxbiosims.org/
2
Christine Simmon retweeted
“The promise of #biosimilars is coming into view, but it won’t be fully realized until more policymakers & physicians understand the value proposition of these FDA-approved treatments.” — @CSimmon_DC @BiosimsCouncil
View report: accessiblemeds.org/resources… #GRxBiosimsSavingsReport
Christine Simmon retweeted
Congress is considering inflation-based rebate penalties in #Medicare to address high brand-name drug costs. AAM SVP @ErikCKomendant shares why this proposal could hurt competition & threaten #patientaccess to affordable #generic & #biosimilar medicines. accessiblemeds.org/resources…
The #GRxBiosims 2021 virtual conference is November 8-10!
Join @AccessibleMeds & the @BiosimsCouncil for invaluable information & insights on generics and biosimilars from industry experts and government officials like @DrWoodcockFDA.
Register here ➡️ grxbiosims.org
September was an exciting month for the @BiosimsCouncil as we announced the topline findings of our 2021 Generic Drug and Biosimilars Savings in the U.S. Report.
Read our September Biosimilars Bulletin here: biosimilarscouncil.org/resou…
1
In this recent article from @MHExecutive, I highlighted the potential savings of #biosimilars and encouraged policymakers to take steps to foster greater biosimilar adoption.
Read more here ⬇️ managedhealthcareexecutive.c…
1
















